Health Technology Kyowa Kirin Co., Ltd. Business Summary
Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.
Financial Highlights
Dec 2022
JPY USD Revenue 398,371M 3,028.80M Gross Profit 301,363M 2,291.25M Operating income 82,375M 626.29M Income before tax 63,249M 480.87M Net income 53,573M 407.31M EBITDA 100,851M 766.76M Diluted EPS 99.65 0.75 Dividends Per Share 51 0.38 Total Assets 939,881M 7,123.27M Total liabilities 177,055M 1,341.88M Total equity 762,826M 5,781.39M Operating cash flow 48,672M 370.05M Currency in JPY Currency in USD
Historical Data Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Revenue
271,510M
305,820M
318,352M
352,246M
398,371M
Gross Profit
188,834M
215,129M
227,827M
253,894M
301,363M
Operating income
50,403M
53,354M
55,419M
61,110M
82,375M
Income before tax
66,841M
44,492M
52,263M
55,475M
63,249M
Net income
49,230M
37,674M
47,027M
52,347M
53,573M
EBITDA
66,646M
72,151M
75,885M
80,608M
100,851M
Diluted EPS
99.29
43.12
87.49
97.38
99.65
Dividends Per Share
35
42
44
46
51
Total Assets
741,982M
784,453M
801,290M
921,872M
939,881M
Total liabilities
92,589M
106,203M
102,893M
184,710M
177,055M
Total equity
649,621M
678,250M
698,396M
737,162M
762,826M
Operating cash flow
56,181M
53,655M
39,502M
86,548M
48,672M
Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Revenue
2,458.37M
2,805.40M
2,981.70M
3,205.93M
3,028.80M
Gross Profit
1,709.78M
1,973.46M
2,133.84M
2,310.79M
2,291.25M
Operating income
456.37M
489.43M
519.05M
556.18M
626.29M
Income before tax
605.20M
408.14M
489.49M
504.90M
480.87M
Net income
445.75M
345.59M
440.45M
476.43M
407.31M
EBITDA
603.44M
661.87M
710.74M
733.64M
766.76M
Diluted EPS
0.89
0.39
0.81
0.88
0.75
Dividends Per Share
0.31
0.38
0.41
0.41
0.38
Total Assets
6,762.81M
7,218.33M
7,761.05M
8,005.48M
7,123.27M
Total liabilities
843.90M
977.25M
996.59M
1,604.01M
1,341.88M
Total equity
5,920.98M
6,241.08M
6,764.45M
6,401.47M
5,781.39M
Operating cash flow
508.68M
492.19M
369.97M
787.70M
370.05M
Valuation Measures
Dec 2022
PER 30.29 ROA 5.75% ROE 7.14% Operating margin 20.67% Profit margin 13.44%
Key executives
President, CEO & Representative Director:
Masashi Miyamoto
Executive Officer, Manager-Accounting & Finance:
Motohiko Kawaguchi
Executive Officer, GM-Research & Development:
Mitsuo Satoh
Representative Director & Executive Vice President:
Yutaka Osawa
Executive Officer & General Manager-Sales:
Hiroshi Sugitani Shareholders
Kirin Holdings Co., Ltd. (53.4%)
Nomura Asset Management Co., Ltd. (3.2%)
Daiwa Asset Management Co. Ltd. (1.6%)
Massachusetts Financial Services Co. (1.5%)
Nikko Asset Management Co., Ltd. (1.5%)
The Vanguard Group, Inc. (1.2%)
BlackRock Fund Advisors (0.9%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.8%)
Norges Bank Investment Management (0.7%)
Goldman Sachs Asset Management Co., Ltd. (Japan) (0.5%)
Contact Details Website: http://www.kyowa-kirin.co.jp Address:
Otemachi Financial City Grand Cube,
1-9-2 Otemachi,
Tokyo,
100-0004,
Japan
Phone:
+81.3.5205.7200
Related Companies
Kyowa Kirin Australia Pty Ltd.
Kyowa Kirin Pharma FZ LLC
Kyowa Kirin Malaysia Sdn. Bhd.
Kyowa Kirin Korea Co., Ltd.
Kyowa Kirin Pharma SRL
Kyowa Kirin Pharma sro
Kyowa Kirin Austria GmbH
Kyowa Kirin SARL
Kyowa Kirin AB
Kyowa Kirin Pharma BV
Kyowa Kirin Holdings BV
Kyowa Kirin Farmaceutica SL
Kyowa Kirin Ireland Ltd.
Kyowa Kirin Canada, Inc.
Kyowa Kirin Frontier Co., Ltd.
Kyowa Medical Promotion Co., Ltd.
Kyowa Kirin GmbH
Strakan International SARL
Kyowa Kirin Plus Co., Ltd.
Kyowa Hakko Bio Co. Ltd. (Beijing)
Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
Kyowa Hakko Kirin (Taiwan) Co. Ltd.
Kyowa Hakko Kirin (Singapore) Pte Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin (Thailand) Co. Ltd.
ProStrakan SRL
Kyowa Hakko Kirin America, Inc.
Competitors
JW Holdings Corporation
Genexine, Inc.
Tonix Pharmaceuticals Holding Corp.
4d Pharma PLC
Vaxxinity Inc Class A
Innate Pharma SA Class A
FibroGen, Inc.
Heron Therapeutics Inc
Tetralogic Pharmaceuticals Corporation
Citius Pharmaceuticals Inc
Ikena Oncology, Inc.
Seagen, Inc.
Connect Biopharma Holdings Ltd. Sponsored ADR
Springworks Therapeutics, Inc.
Prometheus Biosciences, Inc
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Mar, 2023
Take your reading anywhere with offline reading functions Never miss a story with breaking news alerts Customize your reading experience
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close